Abstract 4789: Development of IMC-002, a next-generation anti-CD47 mAb: an affinity optimized antibody with enhanced safety and therapeutic efficacy in preclinical models

Abstract CD47, a broadly expressed transmembrane glycoprotein, interacts with SIRPα to inhibit macrophage-mediated phagocytosis. Its overexpression on cancer cells is associated with poor prognosis, making the CD47-SIRPα axis a promising target for cancer immunotherapy. While blocking this pathway e... View More